1. Pink Sheet
  2. >>R&D

Medivation/Astellas’ Xtandi A Tough Rival For J&J’s Zytiga

 
• By Shirley Haley

Medivation/Astellas’ Xtandi was approved barely a month after FDA announced it had accepted its NDA for post-chemo castration-resistant metastatic prostate cancer, and the newly approved androgen blocker appears to have what it takes to unseat J&J’s market leader Zytiga.

Medivation Inc./Astellas Pharma Inc. may face slower uptake for their prostate cancer drug Xtandi (enzalutamide) than Johnson & Johnson did for Zytiga (abiraterone) because of abiraterone’s foothold, but Xtandi has the potential to overtake the prostate cancer market leader.

FDA’s announcement Aug. 31 that it had approved Xtandi (MDV3100) for treatment of metastatic castration-resistant prostate cancer in men who have already tried docetaxel (Sanofi’s Taxotere and generics) may...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.